Steve Tilles, MD
About Steve Tilles, MD
Steve Tilles, MD, is the Head of Global Medical Affairs for Allergy at Aimmune Therapeutics and a Clinical Professor of Medicine at the University of Washington. He has extensive experience in clinical trials and has authored over 100 papers in peer-reviewed journals.
Work at Aimmune Therapeutics
Steve Tilles serves as the Head of Global Medical Affairs for Allergy at Aimmune Therapeutics. He has held this position since 2022, contributing to the development and management of medical strategies related to allergy treatments. Additionally, he has been a Senior Director of Medical Affairs at Aimmune Therapeutics since 2018, where he has focused on advancing the company's initiatives in allergy care.
Education and Expertise
Steve Tilles earned his Doctor of Medicine (MD) from UC San Diego, where he studied from 1986 to 1990. Prior to this, he completed his Bachelor of Arts (BA) in Biology at Harvard College from 1978 to 1982. His educational background supports his extensive expertise in allergy and immunology, evidenced by his completion of a fellowship in this field at the National Jewish Center for Immunology and Respiratory Medicine.
Background
Steve Tilles has held various academic and clinical positions throughout his career. He worked as a Clinical Associate Professor of Medicine at the University of Washington from 2009 to 2013 and has been a Clinical Professor of Medicine there since 2013. He also served as the Director of the Allergy and Asthma Clinic at Oregon Health Sciences University. His involvement in academia has enhanced his contributions to the field of allergy and immunology.
Achievements
Steve Tilles has been a principal investigator for over 140 clinical trials focused on treatments for conditions such as asthma, allergic rhinitis, urticaria, and atopic dermatitis. He has authored more than 100 papers in peer-reviewed publications, contributing significantly to the body of knowledge in allergy and immunology. His leadership roles include serving as President of the American College of Allergy, Asthma and Immunology from 2016 to 2017 and participating in the Joint Task Force for Practice Parameters and the American Board of Allergy and Immunology.